Achilles Therapeutics Logo RGB Small.jpg
Achilles Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 20, 2022 08:30 ET | Achilles Therapeutics PLC
LONDON, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors,...
Achilles Therapeutics Logo RGB Small.jpg
Achilles Therapeutics Presents Encouraging Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma at ESMO IO Congress 2022
December 06, 2022 06:00 ET | Achilles Therapeutics PLC
- Early proof-of-concept data support durable clinical benefit including confirmed partial response and stable disease in heavily pre-treated patients with advanced NSCLC - - Safety and tolerability...
Achilles Therapeutics Logo RGB Small.jpg
Achilles Therapeutics to Present Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells at the ESMO Immuno-Oncology Annual Congress 2022
November 30, 2022 18:05 ET | Achilles Therapeutics PLC
- Durable partial response (PR) and stable disease (SD) achieved in heavily pre-treated non-small cell lung cancer (NSCLC) patients dosed with cNeT monotherapy - - Updated interim Phase I/II results...
Achilles Therapeutics Logo RGB Small.jpg
Achilles Therapeutics Announces Grant of US Patent on Immunotherapies Targeting Clonal Neoantigens Identified Using Proprietary Method
November 22, 2022 08:00 ET | Achilles Therapeutics PLC
LONDON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors,...
Achilles Therapeutics Logo RGB Small.jpg
Achilles Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
November 08, 2022 07:00 ET | Achilles Therapeutics PLC
- Interim update from the ongoing Phase I/IIa trials in advanced NSCLC (CHIRON) and melanoma (THETIS) to be presented at the ESMO Immuno-Oncology Annual Congress 2022 - - Strong cash balance of...
Achilles Therapeutics Logo RGB Small.jpg
Achilles Therapeutics Co-founder Professor Charles Swanton to Participate in Expert Roundtable Highlighting Pivotal Nature of Neoantigens as Targets in Cancer Cell Therapy
October 06, 2022 08:30 ET | Achilles Therapeutics PLC
Professor Swanton joins Achilles SAB member Dr. Christopher Klebanoff and Dr. John Haanen on the key opinion leader panel to discuss neoantigens as valuable immunotherapy targets Virtual Roundtable...
Achilles Therapeutics Logo RGB Small.jpg
Achilles Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights
August 09, 2022 07:00 ET | Achilles Therapeutics PLC
- Additional clinical data from the ongoing Phase I/IIa trials in advanced NSCLC (CHIRON) and melanoma (THETIS) expected to be available in Q4 2022 - - Cell & Gene Therapy Catapult manufacturing...
Achilles Therapeutics Logo RGB Small.jpg
Achilles Therapeutics to lead Horizon Europe-Funded Consortium to Advance Personalized Cell Therapy Manufacturing
July 21, 2022 08:00 ET | Achilles Therapeutics PLC
LONDON, July 21, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics Logo RGB Small.jpg
Achilles Therapeutics Appoints James Taylor as Chief Business Officer and Cassian Yee, MD to Scientific Advisory Board
June 30, 2022 08:00 ET | Achilles Therapeutics PLC
LONDON, June 30, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics Logo RGB Small.jpg
Achilles Therapeutics Recognized with the 2022 PING Innovation Award
June 21, 2022 08:30 ET | Achilles Therapeutics PLC
LONDON, June 21, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...